SGLT2 inhibitors for fatty liver in type 2 diabetes with kidney disease
Treatments studied
Part of Digestive system, Hormones & metabolism, Kidney & urinary clinical trials.
This study tests whether a class of diabetes drugs called SGLT2 inhibitors can help reduce fat in the liver for people with type 2 diabetes and chronic kidney disease. If you have both conditions, this treatment might improve your liver health.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 20 and 60 years old.
- You have been diagnosed with type 2 diabetes for at least 6 months.
- You have chronic kidney disease stage 3 or 4 (not on dialysis).
- You have fatty liver disease related to metabolic issues.
- You do not have other liver diseases like hepatitis B or C, or cirrhosis.
- You are not severely obese (BMI under 40).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests how a drug called canagliflozin (an SGLT2 inhibitor) affects kidney function in people with type 2 diabetes. It involves two kidney biopsies to see how the drug works inside your kidneys, aiming to better protect kidney health.
This study tests how a type of diabetes medicine called SGLT2 inhibitors affects how the liver makes sugar. It may help researchers better understand how to manage blood sugar in people with type 2 diabetes.
This trial tests how stopping a type 2 diabetes medication called an SGLT2 inhibitor affects the liver's production of sugar and ketones. It may help understand better ways to manage diabetes.
This study tests if adding a diabetes medicine called an SGLT2 inhibitor to your current treatment can help prevent liver complications in people with chronic hepatitis B and type 2 diabetes or prediabetes. If you have early liver scarring and stable diabetes treatment, this could offer extra protection for your liver.
This study tests whether a medicine called henagliflozin can help reduce fat in the liver for people with type 2 diabetes and non-alcoholic fatty liver disease. It may help improve liver health and blood sugar control at the same time.
This study tests whether SGLT2 inhibitors (a type of diabetes drug that also helps kidneys) can help patients with acute kidney disease. It may be an option if you have diabetes or chronic kidney disease along with acute kidney problems.
Hear when a new Effect of SGLT2 Inhibitors NAFLD in Type 2 Diabetic Patients with Diabetic Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.